A Phase I Study of MK-4827 in Combination With Temozolomide in Patients With Advanced Cancer.

Trial Profile

A Phase I Study of MK-4827 in Combination With Temozolomide in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Niraparib; Temozolomide
  • Indications Cancer; Glioblastoma; Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Sep 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2010-0856).
    • 04 Sep 2012 Planned number of patients changed from 54 to 64 as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top